Donald Bobo, Jr. Sells 22,680 Shares of Edwards Lifesciences (NYSE:EW) Stock

Edwards Lifesciences Corporation (NYSE:EW) VP Donald Bobo, Jr. sold 22,680 shares of the business’s stock in a transaction dated Thursday, April 2nd. The shares were sold at an average price of $80.16, for a total value of $1,818,028.80. Following the completion of the transaction, the vice president directly owned 21,266 shares in the company, valued at $1,704,682.56. This represents a 51.61% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Edwards Lifesciences Trading Down 0.5%

Shares of Edwards Lifesciences stock traded down $0.41 on Thursday, hitting $80.85. 3,303,021 shares of the company’s stock traded hands, compared to its average volume of 4,588,320. The company has a fifty day moving average of $81.78 and a two-hundred day moving average of $81.72. Edwards Lifesciences Corporation has a one year low of $65.94 and a one year high of $87.89. The company has a market capitalization of $46.61 billion, a price-to-earnings ratio of 44.18, a price-to-earnings-growth ratio of 2.09 and a beta of 0.94. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.72 and a quick ratio of 3.09.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Tuesday, February 10th. The medical research company reported $0.58 earnings per share for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.04). Edwards Lifesciences had a return on equity of 14.50% and a net margin of 17.69%.The business had revenue of $1.57 billion during the quarter, compared to the consensus estimate of $1.54 billion. During the same quarter in the previous year, the firm posted $0.59 earnings per share. The company’s revenue for the quarter was up 13.3% compared to the same quarter last year. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. As a group, sell-side analysts expect that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Hedge Funds Weigh In On Edwards Lifesciences

Institutional investors have recently modified their holdings of the company. Vanguard Group Inc. grew its position in Edwards Lifesciences by 0.5% in the 3rd quarter. Vanguard Group Inc. now owns 70,363,210 shares of the medical research company’s stock valued at $5,472,147,000 after purchasing an additional 365,581 shares during the period. State Street Corp increased its stake in Edwards Lifesciences by 1.5% during the 4th quarter. State Street Corp now owns 25,991,524 shares of the medical research company’s stock valued at $2,215,777,000 after purchasing an additional 371,892 shares in the last quarter. Wellington Management Group LLP raised its holdings in Edwards Lifesciences by 4.8% during the fourth quarter. Wellington Management Group LLP now owns 21,793,949 shares of the medical research company’s stock worth $1,857,934,000 after buying an additional 989,533 shares during the last quarter. Bank of New York Mellon Corp raised its holdings in Edwards Lifesciences by 8.1% during the third quarter. Bank of New York Mellon Corp now owns 19,010,227 shares of the medical research company’s stock worth $1,478,425,000 after buying an additional 1,423,365 shares during the last quarter. Finally, Jennison Associates LLC lifted its stake in shares of Edwards Lifesciences by 19.6% in the third quarter. Jennison Associates LLC now owns 13,958,774 shares of the medical research company’s stock valued at $1,085,574,000 after buying an additional 2,287,783 shares in the last quarter. 79.46% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research firms recently issued reports on EW. Piper Sandler reiterated an “overweight” rating and set a $100.00 target price (up from $98.00) on shares of Edwards Lifesciences in a research report on Wednesday, February 11th. JPMorgan Chase & Co. upgraded shares of Edwards Lifesciences from a “neutral” rating to an “overweight” rating and raised their price target for the stock from $90.00 to $100.00 in a report on Thursday, December 18th. Stifel Nicolaus set a $110.00 price target on shares of Edwards Lifesciences and gave the company a “buy” rating in a research note on Tuesday, January 20th. Royal Bank Of Canada upped their price objective on shares of Edwards Lifesciences from $95.00 to $100.00 and gave the company an “outperform” rating in a report on Friday, December 5th. Finally, Citigroup reissued a “buy” rating and set a $101.00 price objective (up from $96.00) on shares of Edwards Lifesciences in a research report on Thursday, December 11th. Three analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and nine have issued a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $95.96.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.